Yu Chang

Yu Chang

Auto-generated profile, based on publicly available information

Yu Chang

The First Affiliated Hospital, Jinan University, Guangzhou 510632, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2018 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
XLXin Li
Xin Li
YCYasong Cheng
Yasong Cheng
MZMingzhi Zhang
Mingzhi Zhang
JYJiaqin Yan
Jiaqin Yan
LLLing Li
Ling Li
KYKen He Young
Ken He Young
Natural killer/T-cell lymphoma (NKTCL) is a rare subtype of non-Hodgkin lymphoma that is associated with a poor outcome. Currently, the treatment needs of NKTCL remain unmet, and efforts to further improve treatment are urgently needed. Herein, seven patients with NKTCL who failed to respond to various types of chemotherapies were treated with the anti-programmed death 1 (anti-PD-1) antibody pembrolizumab at 100 mg every 3 weeks. After a median of four cycles of treatment (range 2–18), four out of seven patients responded (two complete response, two partial response, overall response rate 57%). Expression of PD1-ligand available was 50, 20, 30, 70, and 30% of five patients respectively. It is negative in one patient and not tested in one patient. Adverse events, which mostly ranged from grade I to grade III, were tolerable and could be safely handled, although immune-related pneumonitis was notable. Overall, PD-1 blockade with pembrolizumab represents a favorable strategy for the treatment of refractory/relapsed NKTCL.

1 October 2018 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
XZXudong Zhang
Xudong Zhang
XFXiaorui Fu
Xiaorui Fu
MDMeng Dong
Meng Dong
ZYZhenzhen Yang
Zhenzhen Yang
SWShaoxuan Wu
Shaoxuan Wu
QCQingjiang Chen
Qingjiang Chen
Extranodal NK/T-cell lymphoma, nasal type (ENKL) is a distinct clinicopathological entity and EBV-associated disease that is highly aggressive. Many patients had failed to respond to conventional chemotherapy or relapsed after treatment. Multi-drug resistance is a major cause that leads to these desperate failures. However, the specific mechanism of drug resistance is still unclear. In the previous study, we firstly developed a doxorubicin-resistant ENKL cell line known as SNK-6/ADM, and then a small quantity of side population (SP) cells were derived from SNK-6/ADM and named SNK-6/ADM-SP. In order to explore the biological characteristics and mechanism of drug-resistance of these cells, SNK-6, SNK-6/ADM and SNK-6/ADM-SP cells were utilized to evaluate potentially differences of chemotherapy resistance index (RI), morphology, proliferation, cell cycles, expression of ATP-binding cassette (ABC) transporters (ABCG1, ABCG2 and ABCC4) and surface markers, cytokine sensitivity, and situation of EBV infection. We identified SNK-6/ADM-SP is a specific multidrug resistant cell population with a higher level of RI than SNK-6/ADM. Relevant evaluations showed that SNK-6/ADM-SP presented a series of conserved biological behaviors including relatively poor proliferation ability, high expression of ABCG2, weak sensitivity to IL-15 which could stimulate normal ENKL cells’ proliferation and differentiation, and EBV inhibition with low level of EBV-DNA replication and EBV-antigen expression. This discovered cellular heterogeneity of ENKL could provide a new perspective to better understand the mechanisms of drug resistance and overcome elusive response to chemotherapy of ENKL.

1 August 2019 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
WJWeifan Jiang
Weifan Jiang
LDLan Ding
Lan Ding
TDTianming Dai
Tianming Dai
JGJiayin Guo
Jiayin Guo
RDRenke Dai
Renke Dai
YCYu Chang
Yu Chang